Diabetic kidney disease (DKD) represents a major public health issue, currently posing an important burden on healthcare systems. Renin–angiotensin system (RAS) blockers are considered the cornerstone of treatment albuminuric DKD. However, high residual risk progression to more advanced CKD stages under RAS blockade still remains, while relevant studies did not show significant declines in card...